192 related articles for article (PubMed ID: 17324005)
1. Cinacalcet does not affect the pharmacokinetics or pharmacodynamics of warfarin.
Padhi D; Sullivan JT
Drugs R D; 2007; 8(2):79-87. PubMed ID: 17324005
[TBL] [Abstract][Full Text] [Related]
2. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.
Yin OQ; Gallagher N; Fischer D; Zhao L; Zhou W; Leroy E; Golor G; Schran H
Clin Drug Investig; 2011; 31(3):169-79. PubMed ID: 21184622
[TBL] [Abstract][Full Text] [Related]
3. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
Gu N; Kim BH; Lim KS; Kim SE; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
Padhi D; Salfi M; Emery M
Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
[TBL] [Abstract][Full Text] [Related]
5. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
Malhotra B; Alvey C; Gong J; Li X; Duczynski G; Gandelman K
Br J Clin Pharmacol; 2011 Aug; 72(2):257-62. PubMed ID: 21496065
[TBL] [Abstract][Full Text] [Related]
6. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.
Ragueneau-Majlessi I; Levy RH; Meyerhoff C
Epilepsy Res; 2001 Nov; 47(1-2):55-63. PubMed ID: 11673021
[TBL] [Abstract][Full Text] [Related]
7. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
[TBL] [Abstract][Full Text] [Related]
8. Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin.
Mallikaarjun S; Bramer SL
Clin Pharmacokinet; 1999; 37 Suppl 2():79-86. PubMed ID: 10702890
[TBL] [Abstract][Full Text] [Related]
9. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
[TBL] [Abstract][Full Text] [Related]
10. Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin.
Mangold B; Gielsdorf W; Marino MR
Eur J Clin Pharmacol; 1999 Oct; 55(8):593-8. PubMed ID: 10541778
[TBL] [Abstract][Full Text] [Related]
11. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.
Kosoglou T; Zhu Y; Xuan F; Black L; Johnson-Levonas AO; Martinho M; Statkevich P; Cutler DL
Eur J Clin Pharmacol; 2012 Nov; 68(11):1509-16. PubMed ID: 22476387
[TBL] [Abstract][Full Text] [Related]
12. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
Wright DH; Herman GA; Maes A; Liu Q; Johnson-Levonas AO; Wagner JA
J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
[TBL] [Abstract][Full Text] [Related]
13. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.
Stockis A; van Lier JJ; Cawello W; Kumke T; Eckhardt K
Epilepsia; 2013 Jul; 54(7):1161-6. PubMed ID: 23614393
[TBL] [Abstract][Full Text] [Related]
14. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
Schwartz JI; Liu F; Stroh M; Gipson A; Johnson-Levonas AO; Lasseter KC; Lai E; Wagner JA
Am J Ther; 2009; 16(3):215-23. PubMed ID: 19454860
[TBL] [Abstract][Full Text] [Related]
15. Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males.
Schall R; Müller FO; Hundt HK; Duursema L; Groenewoud G; Middle MV
Arzneimittelforschung; 1996 Jan; 46(1):41-6. PubMed ID: 8821516
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers.
Guerret M; Francheteau P; Hubert M
Pharmacotherapy; 1997; 17(4):767-73. PubMed ID: 9250555
[TBL] [Abstract][Full Text] [Related]
17. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects.
Dieterle W; Corynen S; Mann J
Br J Clin Pharmacol; 2004 Oct; 58(4):433-6. PubMed ID: 15373937
[TBL] [Abstract][Full Text] [Related]
18. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin.
Weber C; Banken L; Birnboeck H; Schulz R
J Clin Pharmacol; 1999 Aug; 39(8):847-54. PubMed ID: 10434238
[TBL] [Abstract][Full Text] [Related]
19. Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Krishna R; Stypinski D; Ali M; Garg A; Cote J; Maes A; Degroot B; Liu Y; Li S; Connolly SM; Wagner JA; Stoch SA
Br J Clin Pharmacol; 2012 Jul; 74(1):116-24. PubMed ID: 22243494
[TBL] [Abstract][Full Text] [Related]
20. The effect of aleglitazar on the pharmacokinetics and pharmacodynamics of S- and R-warfarin in healthy male subjects.
Sanwald-Ducray P; Jamois C; Banken L
J Cardiovasc Pharmacol; 2014 Feb; 63(2):152-7. PubMed ID: 24157957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
